Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myeloma PFS boosted by elotuzumab add-on therapy

Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

Key clinical point: Elotuzumab may have synergistic clinical activity with pomalidomide against multiple myeloma.

Major finding: Median progression-free survival was 10.3 months with elotuzumab, pomalidomide, and dexamethasone vs. 4.7 months with pomalidomide and dexamethasone.

Study details: Randomized open-label phase 2 trial of 120 patients with multiple myeloma relapsed or refractory after 2 or more prior lines of therapy.

Disclosures: Bristol-Myers Squibb and AbbVie Biotherapeutics funded the study. Dr. Dimopoulos disclosed honoraria and/or consulting fees from Amgen, BMS, Celgene, Janssen and Takeda.

Source: Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

Read the article.

Citation:

Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.

Must Reads in Multiple Myeloma

Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123

Haploidentical allo-HCT possible even in relapsed myeloma, Sahebi F, et al. Biol Blood Marrow Transplant. 2018 Sep 20. pii: S1083-8791(18)30575-5.

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.